| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| NRG-GI005 | Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA) | Cancer | Gastrointestinal |
| NRG-GY018 | A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer | Cancer | Endometrial |
| NRG-GY019 | Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum https://clinicaltrials.gov/ct2/show/NCT03797326?term=NCT03797326&draw=2&rank=1 | Cancer | Ovarian |
| NRG-HN001 | Randomized Phase II AND Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) | Cancer | Nasopharynx Carcinoma |
| NRG-HN004 | Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin | Cancer | Head and Neck |
| NRG-HN005 | A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer | Cancer | Head and Neck |
| NRG-LU002 | Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung – Cancer | Cancer | Lung |
| NRG-LU005: Limited Stage Small Cell Lung Cancer | A Phase II/III Randomized Study of Chemoradiation VS Chemoradiation Plus Atezolizumab | Cancer | Lung |
| NRG-LU007 | RAndomized Phase II/III Trial Of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR trial | Cancer | Lung |
| NSABP FB-12: | An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected with a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1) | Cancer | Breast |
| ON-TRK | PrOspective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib | Cancer | Genomic |
| PFO Occulder (PAS) | Amplatzer PFO Occluder Post Approval Study (No. SJM-CIP-10187 Ver. A) | Heart & Vascular | Structural Heart Disease |
| Portico NG | This is a study of an updated Portico Valve for TAVR. | Heart & Vascular | Structural Heart Disease |
| RTOG-0724 | Phase III Randomized Study Of Concurrent Chemotherapy and Pelvic Radiation Therapy With Or Without Adjuvant Chemotherapy In High-Risk Patients With Early-Stage Cervical Carcinoma Following Radical Hysterectomy | Cancer | Gynecologic |
| S1608 | Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma | Cancer | Hematology |
| S1703 | Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer | Cancer | Breast |
| S1706 | A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer | Cancer | Breast |
| S1801 | A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma | Cancer | Melanoma |
| S1806 | Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer | Cancer | Genitourinary GU |
| Sync AV | This is a new CRT with optimization turned on or off. | Heart & Vascular | Cardiac Arrhythmia |
| The TESLA Trial | Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke | Neurosciences | Stoke |
| URCC 16070 | Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer | Cancer | Breast |
| A151216 (ALCHEMIST) | Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) | Cancer | Lung |
| Agendia FLEX | The objective of this study is to create a large scale, population-based registry of full genome expression data and clinical data to investigate new gene associations with prognostic and/or predictive value | Cancer | Breast |
| EA6134 | A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma | Cancer | Melanoma |
| EA6141 | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma | Cancer | Melanoma |
| EAY131 (MATCH) | A Molecular Analysis for Therapy Choice (MATCH) - This study is a type of basket trial designed with the flexibility to open and close sub-protocols. Patients enrolled on study will have a tumor biopsy for molecular characterization and those with molecular variants addressed by treatments included in the trial will be offered treatment on MATCH. *Now using outside molecular reports which tumor must be collected within 6 months with no intervening treatment. Foundation One reports will now notify MATCH of molecular matches. | Cancer | Genomic testing based trial |
| NRG BR003 | A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer | Cancer | Breast |
| NRG-GU002 | Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel | Cancer | Prostate |
| S0820 - Prevention of High-Risk Colorectal Polyps and New Colorectal Cancers | PACES S0820 is a study to determine the efficacy of certain drugs in the prevention of high-risk colorectal polyps and new colorectal cancers in patients with previously treated colorectal cancer. | Cancer | Gastro-Intestinal |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.